Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30405284 | 1.00 | RAF1 (1.00) | RAF1BRAF | |
| SCHEMBL16035801 | 1.00 | RAF1 (1.00) | RAF1BRAF | |
| SCHEMBL16095047 | 0.96 | RAF1 (1.00) | RAF1BRAF | |
| SCHEMBL16121460 | 0.96 | RAF1 (1.00) | RAF1BRAF | |
| SCHEMBL16094264 | 0.95 | RAF1 (1.00) | RAF1BRAF | |
| SCHEMBL22473686 | 0.95 | RAF1 (0.91) | RAF1BRAF | |
| SCHEMBL17503437 | 0.95 | RAF1 (1.00) | RAF1BRAF | |
| SCHEMBL17523473 | 0.95 | RAF1 (0.91) | RAF1BRAF | |
| SCHEMBL16121218 | 0.95 | RAF1 (1.00) | RAF1BRAF | |
| SCHEMBL29308909 | 0.95 | RAF1 (0.90) | RAF1BRAF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 372 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4728051-A1 | STANDARDISING PLURIPOTENT STEM CELLS | United Kingdom Research and Innovation (GB) | 2026-04-22 | — | — | EP | claimed |
| EP-3983081-B1 | AMINOPYRIMIDINE AMIDE AUTOPHAGY INHIBITORS AND METHODS OF USE THEREOF | DECIPHERA PHARMACEUTICALS LLC (US) | 2026-03-11 | — | — | EP | claimed |
| EP-4581014-A1 | ULK INHIBITORS AND METHODS OF USE THEREOF | Deciphera Pharmaceuticals, LLC (US) | 2025-07-09 | — | — | EP | claimed |
| US-20250108055-A1 | COMBINATION THERAPIES | MIRATI THERAPEUTICS INC (US) | 2025-04-03 | — | — | US | claimed |
| CN-114072397-B | Heteroaryl aminopyrimidinamide autophagy inhibitors and methods of use thereof | 德西费拉制药有限责任公司 | 2025-03-28 | — | — | CN | claimed |
| CN-119241444-A | Aminopyrimidinamide autophagy inhibitors and methods of use thereof | 德西费拉制药有限责任公司 | 2025-01-03 | — | — | CN | claimed |
| CN-119176782-A | Aminopyrimidinamide autophagy inhibitors and methods of use thereof | 德西费拉制药有限责任公司 | 2024-12-24 | — | — | CN | claimed |
| WO-2024256607-A1 | STANDARDISING PLURIPOTENT STEM CELLS | UNITED KINGDOM RESEARCH AND INNOVATION (GB) | 2024-12-19 | — | — | WO | claimed |
| US-20240390373-A1 | RAF KINASE INHIBITORS FOR TREATING TUMORS HARBORING GENE FUSIONS | DAY ONE BIOPHARMACEUTICALS, INC. | 2024-11-28 | — | — | US | claimed |
| CN-118724900-A | 4-Amino-7-azaindole compound, preparation method and application thereof | 浙江大学智能创新药物研究院 | 2024-10-01 | — | — | CN | claimed |
| US-20220177842-A1 | METHOD FOR LONG-TERM EX VIVO MAINTENANCE OR EXPANSION OF HUMAN ERYTHROBLAST, HUMAN MEGAKARYOCYTE-ERYTHROID PROGENITOR, OR HUMAN COMMON MYELOID PROGENITOR CELL AND APPLICATION THEREOF | OCGENE THERAPEUTICS CORPORATION | 2022-06-09 | — | — | US | claimed |
| WO-2022120153-A1 | METHOD FOR LONG-TERM EX VIVO MAINTENANCE OR EXPANSION OF HUMAN ERYTHROBLAST, MEGAKARYOCYTE-ERYTHROID PROGENITOR, OR COMMON MYELOID PROGENITOR CELL | OCGENE THERAPEUTICS CORPORATION (US) | 2022-06-09 | — | — | WO | claimed |
| EP-3983081-A1 | AMINOPYRIMIDINE AMIDE AUTOPHAGY INHIBITORS AND METHODS OF USE THEREOF | Deciphera Pharmaceuticals, LLC (US) | 2022-04-20 | — | — | EP | claimed |
| WO-2022073994-A1 | LMP7-SELECTIVE INHIBITORS FOR THE TREATMENT OF BLOOD DISORDERS AND SOLID TUMORS | MERCK PATENT GMBH (DE) | 2022-04-14 | — | — | WO | claimed |
| CN-114258318-A | Aminopyrimidine amide autophagy inhibitors and methods of use thereof | 德西费拉制药有限责任公司 | 2022-03-29 | — | — | CN | claimed |
| EP-3966206-A1 | HETEROARYLAMINOPYRIMIDINE AMIDE AUTOPHAGY INHIBITORS AND METHODS OF USE THEREOF | Deciphera Pharmaceuticals, LLC (US) | 2022-03-16 | — | — | EP | claimed |
| EP-3966207-A1 | PHENYLAMINOPYRIMIDINE AMIDE AUTOPHAGY INHIBITORS AND METHODS OF USE THEREOF | Deciphera Pharmaceuticals, LLC (US) | 2022-03-16 | — | — | EP | claimed |
| CN-114127057-A | Phenylaminopyrimidine amide autophagy inhibitors and methods of use thereof | 德西费拉制药有限责任公司 | 2022-03-01 | — | — | CN | claimed |
| US-20220054492-A1 | COMBINATION THERAPIES | Mirati Therapeutics, Inc. | 2022-02-24 | — | — | US | claimed |
| CN-114072397-A | Heteroaryl aminopyrimidine amide autophagy inhibitors and methods of use thereof | 德西费拉制药有限责任公司 | 2022-02-18 | — | — | CN | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250108055-A1 | COMBINATION THERAPIES | KRAS, NRAS, HRAS | RAF1 5/4885BRAF 4/4885 |
| US-20220054492-A1 | COMBINATION THERAPIES | KRAS, NRAS, HRAS | RAF1 5/4885BRAF 4/4885 |
| US-20240390373-A1 | RAF KINASE INHIBITORS FOR TREATING TUMORS HARBORING GENE FUSIONS | BRAF, ARAF, KRAS | RAF1 5/4885BRAF 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.